Firm to lay off 25 employees.
XDx is reprioritizing its business efforts. The firm will increase its research, development, and commercial activities in support of AlloMap®. In addition, it will restructure its internal development program, pursue external research collaborations in lupus, as well as suspend development activities in lung transplant. A staff reduction of 25 positions and other cost-saving measures will be undertaken as well.

Previous articleLilly Finalizes Acquisition of ImClone Systems
Next articleBristol-Myers Squibb Exercises Option to Develop Another Exelixis Drug Candidate